

Row No	REC no	IRAS No	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
1	16/NE/0384	209045	PARADISE-MI	Number Agreed	5	5	Date Agreed	13/03/2020	16	13/03/2020	16	Recruitment Finished
2	17/LO/0402	209419	IMmotion010	Number Agreed	3	3	Date Agreed	12/11/2019	3	12/11/2019	3	Recruitment Finished
3	15/NE/0350	181479	RESP 3213 (Lung Volume Reduction Coil)	Number Agreed	15	15	Date Agreed	12/11/2019	16	12/11/2019	16	Recruitment Finished
4	17/WM/0308	226910	ALPINE 2: AZLI for children with CF and PA lung infection	Number Agreed	2	2	Date Agreed	09/04/2020	3	09/04/2020	3	Recruitment Finished
5	17/EE/0177	220722	BOSTON: Open-label Study of SVD versus VD in patients with RMM	Number Agreed	5	5	Date Agreed	12/11/2019	5	12/11/2019	5	Recruitment Finished
6	17/EM/0412	234907	Safety and efficacy study of LNP023 in IgA Nephropathy	Number Agreed	2	2	Date Agreed	05/07/2020	2	05/07/2020	2	Recruitment Finished
7	18/EM/0326	252819	Action of Tezepelumab on airway inflammation in moderate-severe asthma	Number Agreed	8	8	Date Agreed	13/02/2020	10	13/02/2020	10	Recruitment Finished
8	19/LO/0855	260338	NKTR-214 Phase II urothelial cancer with low PD-L1 expression Study	Number Agreed	1	1	Date Agreed	25/05/2020	4	25/05/2020	4	Recruitment Finished
9	12/NW/0694	109044	MCRN150 (A0221047)	Number Agreed	2	2	Date Agreed	07/11/2019	0	07/11/2019	0	Recruitment Finished
10	16/NW/0041	197706	CANC - 4492 - SOLAR-1	Number Agreed	8	8	Date Agreed	26/02/2020	2	26/02/2020	2	Recruitment Finished
11	16/EE/0183	199109	MUSC 3998	Number Agreed	1	1	Date Agreed	12/11/2019	0	12/11/2019	0	Recruitment Finished
12	17/NE/0092	220929	B5091007 - C.Difficile infection-9002/0359-Pfizer	Number Agreed	18	18	Date Agreed	12/11/2019	7	12/11/2019	7	Recruitment Finished
13	16/EE/0463	214371	ComPLEment-1	Number Agreed	5	5	Date Agreed	30/10/2019	2	30/10/2019	2	Recruitment Finished
14	16/NW/0620	206738	Pro2tect-Correction	Number Agreed	2	2	Date Agreed	12/11/2019	0	12/11/2019	0	Recruitment Finished
15	17/EM/0058	221776	1245.110 EMPEROR-Preserved Study	Number Agreed	6	6	Date Agreed	12/12/2019	1	12/12/2019	1	Recruitment Finished
16	18/LO/0416	235395	Evaluation of Avelumab combined with Talazoparib in solid tumours	Number Agreed	5	5	Date Agreed	07/10/2019	3	07/10/2019	3	Recruitment Finished
17	17/LO/1672	209107	MDS Clinical Utility Study OMS002-1	Number Agreed	100	100	Date Agreed	12/11/2019	68	12/11/2019	68	Recruitment Finished
18	18/YH/0055	241341	Jazz JZP963-201	Number Agreed	3	3	Date Agreed	22/10/2019	1	22/10/2019	1	Recruitment Finished
19	18/EM/0217	244390	ANTHEM	Number Agreed	4	4	Date Agreed	05/11/2019	0	05/11/2019	0	Recruitment Finished
20	18/EE/0296	250366	Comparison of AZD9977 with Spironolactone in Heart Failure	Number Agreed	3	3	Date Agreed	16/03/2020	1	16/03/2020	1	Recruitment Finished
21	19/EE/0014	256539	IXchange	Number Agreed	2	2	Date Agreed	10/12/2019	0	10/12/2019	0	Recruitment Finished
22	19/EM/0101	260487	SCENIC Trial	Number Agreed	5	5	Date Agreed	01/05/2020	1	01/05/2020	1	Recruitment Finished
23	19/NW/0181	260431	RELIEF	Number Agreed	5	5	Date Agreed	22/07/2020	3	22/07/2020	3	Recruitment Finished
24	19/EE/0200	265253	Investigating tirzepatide versus semaglutide in Type 2 Diabetes	Number Agreed	8	8	Date Agreed	17/01/2020	1	17/01/2020	1	Recruitment Finished
25	19/LO/1500	269558	BASIC Study PMCF	Number Agreed	4	4	Date Agreed	31/08/2020	0	31/08/2020	0	Recruitment Finished